Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01296932).
- BIANCAIndependent statistical analysis of Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1): Complete Statistical AnalysisIndependent statistical analysis of BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1): primary endpoint results, effect estimate with confidence interval,…
- BIG 1-98A detailed statistical analysis of BIG 1-98, a randomized phase 3 trial of letrozole and tamoxifen citrate in postmenopausal women with breast cancer, focusing on disease-free survival and its time-to-event analysis.
- BILCAPIndependent statistical analysis of the BILCAP phase 3 trial evaluating capecitabine or observation after surgery in patients with biliary tract cancer, including trial design, the 2-year survival endpoint, statistical methodology, and interpretation.
- Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: Complete Statistical AnalysisIndependent statistical analysis of Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BIOGUIDE-XIndependent statistical analysis of Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor: Complete Statistical AnalysisIndependent statistical analysis of Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BIRCHIndependent statistical analysis of A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…
- Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission: Complete Statistical AnalysisIndependent statistical analysis of Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BMS 247550 to Treat Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of BMS 247550 to Treat Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00030992).
- BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT): Complete Statistical AnalysisIndependent statistical analysis of BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Body Mind Training Project: Complete Statistical AnalysisIndependent statistical analysis of Body Mind Training Project: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01564394).
- BOLTIndependent statistical analysis of A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: Complete Statistical AnalysisIndependent statistical analysis of Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Booster Dose Trial: Complete Statistical AnalysisIndependent statistical analysis of Booster Dose Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05016622).
- Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00075881).
- Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00440726).
- Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence…
- Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin’s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: primary endpoint results, effect estimate with…
- Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis:…
- BOSTONIndependent statistical analysis of the phase 3 BOSTON trial of selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in multiple myeloma, including PFS, response, overall survival, safety, and statistical methodology.
- Bosutinib in Adult Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bosutinib in Adult Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01331291).
- Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia: Complete Statistical AnalysisIndependent statistical analysis of Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BR.21An independent statistical analysis of BR.21, the randomized phase 3 trial of OSI-774 (Tarceva, erlotinib HCl) in patients with stage III or stage IV non-small cell lung cancer.
- Break MBIndependent statistical analysis of A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BREAKWATERIndependent statistical analysis of the BREAKWATER phase 3 trial of encorafenib plus cetuximab with or without chemotherapy in previously untreated metastatic colorectal cancer, including trial design, primary endpoints, hazard ratios, odds ratios,…
- Breast Cancer Risk Biomarkers in Postmenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of Breast Cancer Risk Biomarkers in Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01252290).
- BreastCAREIndependent statistical analysis of Breast Cancer Risk Reduction: A Patient Doctor Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01830933).
- BretuximabIndependent statistical analysis of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Brigatinib Before Brain Irradiation Trial (B3i Trial): Complete Statistical AnalysisIndependent statistical analysis of Brigatinib Before Brain Irradiation Trial (B3i Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04634110).
- BRIGHTIndependent statistical analysis of Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) 2.0: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BRIGHT AML1019Independent statistical analysis of A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia: primary endpoint results, effect estimate…
- Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BRPIndependent statistical analysis of IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BrTK02Independent statistical analysis of Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…